FDA Panel To Ponder Approval Factors For OTC Infectious Disease Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to hold an advisory panel meeting in mid-August to discuss the potential risks and benefits of clearing or approving over-the-counter infectious disease tests.
You may also be interested in...
OraSure Preps October Launch Of First-Ever In-Home HIV Test
Firm gains PMA approval for OraQuick July 3, making it the first available HIV test that can be performed entirely in the home by untrained users.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.
Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.